Jennison Associates LLC Genmab A/S Transaction History

Jennison Associates LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$30.92 - $44.4 $44.2 Million - $63.5 Million	-1,429,842 Closed	0 $0
Q4 2020 Feb 05, 2021	BUY	$33.66 - $40.76 $11.8 Million - $14.3 Million	349,845 Added 32.39%	1,429,842 $58.1 Million
Q3 2020 Nov 04, 2020	BUY	$33.07 - $38.68 $16 Million - $18.7 Million	482,908 Added 80.88%	1,079,997 $39.5 Million
Q2 2020 Aug 06, 2020	BUY	$20.05 - $33.89 $36,230 - $61,239	1,807 Added 0.3%	597,089 $20.2 Million
Q1 2020 May 06, 2020	BUY	$17.15 - $25.22 $10.2 Million - $15 Million	595,282 New	595,282 $12.6 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.